Update on neutropenia and myeloid growth factors.
Crawford
Jeffrey
J
Department of Medicine, Duke University Medical Center, DUMC 3476, Durham, NC 27710, USA. crawf006@mc.duke.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003115:Colony-Stimulating Factors / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000191:economics; D011092:Polyethylene Glycols; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D018570:Risk Assessment
D003115:Colony-Stimulating Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim